Belimumab

贝利尤单抗

Report date: 2026/04/22 20:01:10
First In Class

Base Information

Drug NameBelimumab
Drug Alias Name贝利目单抗Anti-BLyS monoclonal antibody贝利木单抗belimumab贝利单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsRejection of renal transplantationsystemic sclerosis-associated interstitial lung diseaseEmphysema +[25] 
Global Approved IndicationsLupus Erythematosus, Systemic
Approved Indications in ChinaLupus Erythematosus, Systemic
Original Approved Country/TerritoryUnited States
Original Approved Date2011/03/09
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[13] 
Inactive CompaniesGlaxosmithkline Research & Development LtdUniversity Of UdineGlaxo Group Limited, England +[8] 
Active IndicationsRejection of renal transplantationsystemic sclerosis-associated interstitial lung diseaseEmphysema +[16] 
Inactive IndicationsSjogren-Larsson SyndromePurpuraAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[9] 

Other Information

ATC CodeL04AG04
Related LinksWikipediaDrugBankKEGG